Evidence map›Paper›PMID 36388799›Full record

ArticleAnnals of translational medicine2022

Complete response to sotorasib as neoadjuvant treatment in patient with locally advanced primary pulmonary sarcoma harboring

Ce Li, Yanan Wang, Yongyang Yu, Wei Li, Tao Guo, Yongle Li, Hefei Li

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ce Li *Department of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, China.
Yanan Wang *Department of Pathology, Affiliated Hospital of Hebei University, Baoding, China.
Yongyang YuDepartment of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, China.
Wei LiDepartment of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, China.
Tao GuoDepartment of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, China.
Yongle LiDepartment of Anesthesiology, Affiliated Hospital of Hebei University, Baoding, China.
Hefei LiDepartment of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, China.
Affiliated Hospital of Hebei University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary pulmonary sarcoma (PPS) is very rare relative to other subtypes of lung cancer. Therefore, evidence-based treatment options for PPS patients have remained unclear. Identification of actionable cancer driver mutations in patients with non-small cell lung cancer (NSCLC) has provided the chance to use targeted treatments and improve patient clinical outcomes. In addition to epidermal growth factor receptor ( Case Description: In our study, we reported a locally advanced PPS patient harboring Conclusions: To our knowledge, it was the first study to use sotorasib for a PPS patient harboring

Indexed as

Case reportcomplete response (CR)Kirsten rat sarcoma G12C (KRAS G12C)primary pulmonary sarcoma (PPS)video-assisted thoracoscopic surgery (VATS)

Identifiers

PMID36388799
PMCPMC9652552
OpenAlexW4307708328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.